December 11, 2017

Sage Therapeutics Reports Successful Depression Drug Study

08 December 2017, 10:22 | Henrietta Morgan

Does Sage Therapeutics, Inc. (SAGE) Have More Gas After Achieving 52-Week High?

SAGE | Stocks Latest Headlines for Sage Therapeutic Com -

Sage Therapeutics shares are once again rocketing up this morning, this time based on positive results from a small Phase II study of an oral version of their depression therapy. (NASDAQ:SAGE). Denver Advisors Ltd Liability Com has invested 0.02% of its portfolio in Sage Therapeutics, Inc. Dupont Cap accumulated 13,528 shares.

Long one of the most volatile stocks in biotech, Sage says that SAGE-217 clearly hit the goal post for statistical significance in major depressive disorder, achieving a 64% success rate in achieving clinical remission on a commonly used score for depression against 23% on a placebo.

Trading stocks at an all time highs is usually a winning strategy. State of Wisconsin Investment Board acquired a new position in Sage Therapeutics during the second quarter valued at approximately $1,991,000.

IFM Investors Pty Ltd Raises Holdings in Chevron Corporation (CVX)
The stock of Chevron Corporation (NYSE: CVX ) has "Buy" rating given on Friday, September 22 by BMO Capital Markets. Chevron comprises 1.4% of IFM Investors Pty Ltd's investment portfolio, making the stock its 15th largest holding.

SAGE has been the subject of several other research reports. J P Morgan Chase & Co lowered their price target on shares of Sage Therapeutics from $99.00 to $85.00 and set an "overweight" rating for the company in a research report on Tuesday, September 12th. (NASDAQ:SAGE). Jabre Sa has invested 0.03% of its portfolio in Sage Therapeutics, Inc. ValuEngine upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, August 28th. About 6.61 million shares traded or 676.95% up from the average. Tightening the gaze, stock performance for the last 5 trading days is -2.39%. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.40. Sage Therapeutics has a 12 month low of $44.55 and a 12 month high of $100.50. Therefore 88% are positive.

In the grander scheme, "While some investors may want to take profits (with stock up 75% before the open), we think the long-range prospects for SAGE are positive and maintain our BUY rating". From the opening price, the stock has seen a change of -0.40% recently clocking in with a price of $160.54. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with "Buy" rating in Thursday, November 9 report. Bank of America maintained the shares of SAGE in report on Thursday, November 16 with "Buy" rating. The firm earned "Buy" rating on Tuesday, September 12 by Leerink Swann. Stifel Nicolaus maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, June 29 with "Outperform" rating. The firm has "Buy" rating given on Tuesday, September 12 by Canaccord Genuity. As per Thursday, December 7, the company rating was maintained by Leerink Swann.

More recent Sage Therapeutics, Inc.

No change in our policy on Palestine, says India
The statement however did not specifically address the issue of Jerusalem as the USA -recognised capital of Israel. PM Modi had skipped Palestine during his visit to Israel in July.

SAGE Therapeutics Inc (NASDAQ:SAGE) is roaring up almost 77% through the market ceiling after a massively successful Phase 2 read-out in major depressive disorder (MDD), earning a new shot of confidence from an already positive bull on the Street.

Praising the depression drug's safety profile, the analyst elaborates: "Safety clean, highly encouraging SAGE-217 showed a clean safety profile with adverse events consistent with prior studies, including headache, dizziness, nausea, and somnolence". (NASDAQ:SAGE) were released by: and their article: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" published on December 07, 2017 as well as's news article titled: "Mid-Day Market Update: Duluth Holdings Drops Following Q3 Results; SAGE ..." with publication date: December 07, 2017. Hershey Trust Co. bought a new position in shares of Sage Therapeutics in the 3rd quarter worth about $118,000. The company has market cap of $22.06 million. "There has been little innovation in the discovery and development of treatments for depression in the last two decades", Sage's chief executive, Jeff Jonas, said in a statement.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. It now has negative earnings.

The ASX is replacing its CHESS share clearing system with blockchain technology
Digital Asset Holdings LLC, the blockchain startup run by former JPMorgan Chase & Co. banker Blythe Masters , will supply the technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other News

Trending Now

PlayerUnknown's Battlegrounds Reveals First Gameplay of Desert Map Miramar
It contains some denser urban areas, including a massive city far larger than anything the game has offered thus far. It will be officially released with the launch of the game's 1.0 release on December 20th.

International Monetary Fund identifies financial risks in China
But it said it did not go along with all of the findings and that the stress tests "do not fully reflect the whole picture". Increasing capital would enhance the resilience and credibility of the financial system, as well as reassure markets.

Huawei brings Android 8.0 Oreo to its Honor V9 and Honor 9
It is powered by a Kirin 960 octa-core SoC paired with 4GB of RAM and either 64GB or 128GB onboard storage options. Huawei Mate 9 was launched back in November a year ago , in case you don't manage to recall.

THQ Nordic's New Survival Game Enters Early Access Next Week
Fade to Silence promises dynamic, accumulating snow, real-time snow trails, and completely immersive weather effects. Players will assume control of Ash, a "natural but tormented leader" forced to survive a harsh winter.

Rafael Palmeiro, 53, considers a comeback
I've been working out for years. "There's no doubt in my mind I can do it", Palmeiro told Rosenthal, per Yahoo's Chris Cwik. As of right now, Minoso, a White Sox legend, is the fourth-oldest player to appear in a Major League Baseball game.

Marsh & McLennan Companies (MMC) Receiving Somewhat Positive News Coverage, Study Finds
Jefferies downgraded the shares of IP in report on Tuesday, May 3 to "Hold" rating. (NYSE: MMC ) rating on Monday, October 2. Ameriprise Financial Inc. increased its stake in shares of Marsh & McLennan Companies by 2.2% in the first quarter.

Competing Reviews of Woody Allen's Wonder Wheel
Humpty ( Jim Belushi ), Carolina's father and Ginny's husband, struggles with his alcohol abuse and the return of his daughter. It also shows how things in life can change like the seasons but that they also often stay exactly the same.

First Warning Forecast: Dropping Temps And Snow
WEATHER BRAINS: You can listen to our weekly 90-minute netcast anytime on the web, or on iTunes . It is important to note that not everyone in the Winter Weather Advisory will see snow.

In the Valley of Gods Is the New Game from Campo Santo
We're now developing the game for Windows, Mac, and Linux, with any potential future platforms yet to be determined. In the Valley of Gods is now in development and does not yet have a release date or system requirements.

Federal High Court judge resigns
Justice Ademola was said to have sent his resignation Wednesday after presiding over several cases, four of which were criminal matters.